Comparison of haploidentical stem cell transplant outcomes using PTCy for pediatric hematologic malignancies
| Reference . | N . | Donor type . | Disease . | Grade I-II aGVHD . | Grade III-IV aGVHD . | Mod-severe cGVHD . | Graft failure . | TRM . | Relapse . | EFS . |
|---|---|---|---|---|---|---|---|---|---|---|
| Fierro et al (2023)11 | 32 | Haplo (BM) | AL/MDS | 13% | 0% | 4% | 9% | 0% | 32% | 68% |
| Symons et al (2020)14 | 29 | Haplo | AL/MDS | 17% | 4% | 14% | N/A | 7% | 28% | 69% |
| Sharma et al (2021)10 | 17 | Haplo (PBSC) | AL | 12% | 12% | 18% | 5.8% | 5.8% | 29% | 64.7% |
| Srinivasan et al (2022)15 | 26 | Haplo (PBSC) | Heme malignancy | N/A | 11.5% | 9.2% | 3.8% | 0% | 19.3% | 73.8% |
| Hong et al (2022)16 | 35 | Haplo (PBSC) | AL | 34.3% | 2.9% | 11.4% | 0% | 0% | 25.6% | 74.4% |
| Reference . | N . | Donor type . | Disease . | Grade I-II aGVHD . | Grade III-IV aGVHD . | Mod-severe cGVHD . | Graft failure . | TRM . | Relapse . | EFS . |
|---|---|---|---|---|---|---|---|---|---|---|
| Fierro et al (2023)11 | 32 | Haplo (BM) | AL/MDS | 13% | 0% | 4% | 9% | 0% | 32% | 68% |
| Symons et al (2020)14 | 29 | Haplo | AL/MDS | 17% | 4% | 14% | N/A | 7% | 28% | 69% |
| Sharma et al (2021)10 | 17 | Haplo (PBSC) | AL | 12% | 12% | 18% | 5.8% | 5.8% | 29% | 64.7% |
| Srinivasan et al (2022)15 | 26 | Haplo (PBSC) | Heme malignancy | N/A | 11.5% | 9.2% | 3.8% | 0% | 19.3% | 73.8% |
| Hong et al (2022)16 | 35 | Haplo (PBSC) | AL | 34.3% | 2.9% | 11.4% | 0% | 0% | 25.6% | 74.4% |
AL, acute leukemia; BM, bone marrow; haplo, haploidentical; TRM, treatment related mortality.